Schizophrenia

Previous studies have shown that some 5HT2c agonists may have relevance for the treatment of particular types of neurological conditions. Certain potent and highly selective compounds that we have developed display a profile that we believe may have utility in treating schizophrenia. We evaluated some of these compounds in preclinical models of schizophrenia and have observed that they exhibit efficacy and safety in these models. We are currently exploring partnering opportunities for this program and may elect to enter into a partnership to advance the development of this program for the treatment of obesity and related indications, schizophrenia, or multiple indications.

If you are a qualified researcher or potential partner interested in collaborating with us to explore the potential application of MultiStem for the treatment of a specific clinical indication or disease state, please contact us collaborations@athersys.com. All inquiries regarding potential collaborations will be handled in a discreet and confidential manner.